Paysign reports FY2022 revenue $38.0M (+29% YoY), net income $1.0M; guides FY2023 revenue $44-46M

Paysign, Inc.

Full-year 2022 revenue $38.0M, up 29% YoY; net income $1.0M ($0.02 diluted EPS) vs net loss of $2.7M in 2021.
Adjusted EBITDA $5.5M, up 175% from $2.0M; Q4 revenue $10.6M, up 21%; Q4 adjusted EBITDA $1.7M, up 38%.
Board authorized $5M share repurchase program; added 78 net plasma centers in 2022, ending with 444.
FY2023 guidance: revenue $44-46M, net income $2.5-3.5M ($0.05-0.06 diluted EPS), adjusted EBITDA $6.0-7.5M.
Pharma copay revenue up 145% to $1.5M; launched 10 new pharma copay programs in 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Paysign, Inc. reported full-year 2022 results: revenue $38.0 million, net income $1.0 million, EPS $0.02.

Period: full-year 2022
Revenue: $38.0 million
Net income: $1.0 million
EPS: $0.02
Result: reported results

Exact text from the filing

Full-year 2022 total revenues of $38.0 million, up 29% from full-year 2021 · Full-year 2022 net income of $1.0 million, or diluted earnings per share of $0.02

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Paysign, Inc. reported the fourth quarter 2022 results: revenue $10.6 million, net income $0.7 million, EPS $0.01.

Period: the fourth quarter 2022
Revenue: $10.6 million
Net income: $0.7 million
EPS: $0.01
Result: reported results

Exact text from the filing

Fourth quarter total revenues of $10.6 million, up 21% from fourth quarter 2021 · Fourth quarter net income of $0.7 million, or diluted earnings per share of $0.01

View on SEC.gov

Browse all earnings releases →

Paysign, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-001648

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.